A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Acyclovir (Acyclovir suspension)

Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor class · 34 generic manufacturers · 56 ANDAs filed at FDA.

First FDA approval1982-03-29
Generic availableYes · 34 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$55.7M in CY2024 Part D spend3.0M claims · 1.2M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.077/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.090
Across all dosage forms in distribution.
Highest NADAC
$0.097
Range is tight.
Plans with PA
380 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Acyclovir used for?

Acyclovir is a Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Acyclovir?

Yes. 56 ANDAs filed at FDA, 34 generic manufacturers currently shipping.

How much does my plan pay for Acyclovir?

Across 329 Part D plans, Acyclovir averages $0.090/unit (NADAC). Lowest available: $0.077/unit. Highest in distribution: $0.097/unit.

Is Acyclovir on the FDA shortage list?

No. Acyclovir is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor2 alternatives in D1
01
Acyclovir and Hydrocortisone
Brand: Xerese
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Famciclovir
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
$0.270Lowest NADAC
5Generic mfrs
$9.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.